CA3242509A1 - Respiratory stimulant parenteral formulations - Google Patents
Respiratory stimulant parenteral formulationsInfo
- Publication number
- CA3242509A1 CA3242509A1 CA3242509A CA3242509A CA3242509A1 CA 3242509 A1 CA3242509 A1 CA 3242509A1 CA 3242509 A CA3242509 A CA 3242509A CA 3242509 A CA3242509 A CA 3242509A CA 3242509 A1 CA3242509 A1 CA 3242509A1
- Authority
- CA
- Canada
- Prior art keywords
- parenteral formulations
- respiratory stimulant
- compound
- disclosed
- stimulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293985P | 2021-12-27 | 2021-12-27 | |
| US63/293,985 | 2021-12-27 | ||
| US202263313472P | 2022-02-24 | 2022-02-24 | |
| US63/313,472 | 2022-02-24 | ||
| PCT/US2022/053935 WO2023129502A1 (en) | 2021-12-27 | 2022-12-23 | Respiratory stimulant parenteral formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242509A1 true CA3242509A1 (en) | 2023-07-06 |
Family
ID=86992921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242509A Pending CA3242509A1 (en) | 2021-12-27 | 2022-12-23 | Respiratory stimulant parenteral formulations |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230210857A1 (enExample) |
| EP (1) | EP4456900A4 (enExample) |
| JP (1) | JP2025501169A (enExample) |
| KR (1) | KR20240150426A (enExample) |
| AU (1) | AU2022426492A1 (enExample) |
| CA (1) | CA3242509A1 (enExample) |
| MX (1) | MX2024008162A (enExample) |
| TW (1) | TW202333732A (enExample) |
| WO (1) | WO2023129502A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4543455A4 (en) * | 2022-06-24 | 2026-06-03 | Enalare Therapeutics Inc | METHODS OF TREATMENT FOR NEUROLOGICAL VENTILATORY FAILURE |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69729880T3 (de) * | 1996-12-24 | 2012-05-10 | Biogen Idec Ma Inc. | Stabile flüssige interferon-zubereitungen |
| SG10201601507YA (en) * | 2010-11-29 | 2016-04-28 | Galleon Pharmaceuticals Inc | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
| US20120295911A1 (en) * | 2010-11-29 | 2012-11-22 | Galleon Pharmaceuticals, Inc. | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
| AU2012250050B2 (en) * | 2011-04-28 | 2017-04-06 | Platform Brightworks Two, Ltd. | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
| BR112015011213A2 (pt) * | 2012-11-15 | 2017-08-29 | Galleon Pharmaceuticals Inc | Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição. |
| GB201502412D0 (en) * | 2015-02-13 | 2015-04-01 | Canbex Therapeutics Ltd | Therapeutic use |
-
2022
- 2022-12-23 JP JP2024539090A patent/JP2025501169A/ja active Pending
- 2022-12-23 WO PCT/US2022/053935 patent/WO2023129502A1/en not_active Ceased
- 2022-12-23 AU AU2022426492A patent/AU2022426492A1/en active Pending
- 2022-12-23 EP EP22917259.8A patent/EP4456900A4/en active Pending
- 2022-12-23 MX MX2024008162A patent/MX2024008162A/es unknown
- 2022-12-23 KR KR1020247025381A patent/KR20240150426A/ko active Pending
- 2022-12-23 US US18/088,137 patent/US20230210857A1/en active Pending
- 2022-12-23 CA CA3242509A patent/CA3242509A1/en active Pending
- 2022-12-27 TW TW111150221A patent/TW202333732A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4456900A1 (en) | 2024-11-06 |
| TW202333732A (zh) | 2023-09-01 |
| WO2023129502A1 (en) | 2023-07-06 |
| KR20240150426A (ko) | 2024-10-15 |
| US20230210857A1 (en) | 2023-07-06 |
| MX2024008162A (es) | 2024-09-17 |
| JP2025501169A (ja) | 2025-01-17 |
| EP4456900A4 (en) | 2025-12-24 |
| AU2022426492A1 (en) | 2024-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022125616A8 (en) | Dialkyl tryptamines and their therapeutic uses | |
| AU2021323253A8 (en) | Heterocyclic GLP-1 agonists | |
| WO2023192602A3 (en) | Respiratory stimulant nasal formulations | |
| MX2021003739A (es) | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. | |
| NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| SG10201407538WA (en) | Intravenous formulations of neurokinin-1 antagonists | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| EP4706683A3 (en) | Chewable formulations | |
| PH12022553024A1 (en) | Inhibitors of nek7 kinase | |
| MX2024014628A (es) | Compuesto para inhibir o degradar bcl6 y uso de este en farmacia | |
| NO20051389L (no) | Stabilisert farmasoytisk blanding inneholdende basiske hjelpemidler | |
| WO2023129956A3 (en) | Dimethyltryptamine analogues as nitric oxide delivery drugs | |
| SG165162A1 (en) | Modified release pharmaceutical formulation | |
| PH12023552774A1 (en) | Nek7 inhibitors | |
| MX2024009177A (es) | Compuestos y metodos de uso | |
| MY200061A (en) | Irak inhibitor and preparation method therefor and use thereof | |
| MX2024008162A (es) | Formulaciones parenterales estimulantes respiratorias. | |
| MX2023009052A (es) | Compuesto de bifenilo como inmunomodulador, método de preparación para el mismo y uso del mismo. | |
| MX2025005209A (es) | Compuestos lipídicos y usos de los mismos | |
| MX2022015495A (es) | Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7). | |
| MX2025002355A (es) | Compuestos de triazina y usos de los mismos | |
| GEAP202516737A (en) | Compounds for treating cancer | |
| SE0201658D0 (sv) | Immediate release pharmaceutical formulation | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| CA2490335A1 (en) | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241213 |